CSIMarket Company Name, Ticker, Suppliers, else..


Amneal Pharmaceuticals Inc   (NASDAQ: AMRX)
Other Ticker:  
 

Amneal Pharmaceuticals Inc

AMRX's Fundamental analysis



Looking into Amneal Pharmaceuticals Inc growth rates, revenue grew by 31.27 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 1161

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.85 %

Amneal Pharmaceuticals Inc faced net loss in contrast to the net income a year ago in IV. Quarter 2024

• More on AMRX's Growth


Amneal Pharmaceuticals Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 96.68 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.79.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.


• More on AMRX's Valuation
 
 Total Debt (Millions $) 2,386
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 362,563
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 7.98
 Tangible Book Value (Per Share $) -4.68

Amneal Pharmaceuticals Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 96.68 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.79.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.


• More on AMRX's Valuation

•  Market Capitalization (Millions $) 2,205
•  Shares Outstanding (Millions) 308
•  Employees 7,700
•  Revenues (TTM) (Millions $) 2,792
•  Net Income (TTM) (Millions $) -192
•  Cash Flow (TTM) (Millions $) 23
•  Capital Exp. (TTM) (Millions $) -96
•  Total Debt (Millions $) 2,386
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 362,563
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) 7.98
•  Tangible Book Value (Per Share $) -4.68

•  Market Capitalization (Millions $) 2,205
•  Shares Outstanding (Millions) 308
•  Employees 7,700
•  Revenues (TTM) (Millions $) 2,792
•  Net Income (TTM) (Millions $) -192
•  Cash Flow (TTM) (Millions $) 23
•  Capital Exp. (TTM) (Millions $) -96


    AMRX's Profitability Comparisons
Amneal Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 11.76 % from 12.66 % in III. Quarter.




Profitability by Segment
Generics 41.65 %
Specialty 54.74 %
AvKARE 17.72 %
Total 1.68 %



  Ratio
•   Capital Ratio (MRQ) 1.41
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.8
•  Inventory Turnover Ratio (TTM) 3.07



Amneal Pharmaceuticals Inc faced margin deterioration, primarily through cost control. Operating Margin fell in IV. Quarter 2024 to 11.76 % from 12.66 % in III. Quarter.



• More on AMRX's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com